Browse NPRL3

Summary
SymbolNPRL3
NameNPR3-like, GATOR1 complex subunit
Aliases CGTHBA; RMD11; MARE; HS-40; conserved gene telomeric to alpha globin cluster; C16orf35; chromosome 16 open r ......
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Lysosome membrane Note=Localization to lysosomes is amino acid-independent.
Domain PF03666 Nitrogen Permease regulator of amino acid transport activity 3
Function

As a component of the GATOR1 complex functions as an inhibitor of the amino acid-sensing branch of the TORC1 pathway. The GATOR1 complex strongly increases GTP hydrolysis by RRAGA and RRAGB within RRAGC-containing heterodimers, thereby deactivating RRAGs, releasing mTORC1 from lysosomal surface and inhibiting mTORC1 signaling. The GATOR1 complex is negatively regulated by GATOR2 the other GATOR subcomplex in this amino acid-sensing branch of the TORC1 pathway.

> Gene Ontology
 
Biological Process GO:0000045 autophagosome assembly
GO:0003205 cardiac chamber development
GO:0003231 cardiac ventricle development
GO:0003279 cardiac septum development
GO:0003281 ventricular septum development
GO:0006914 autophagy
GO:0007033 vacuole organization
GO:0007507 heart development
GO:0009267 cellular response to starvation
GO:0009991 response to extracellular stimulus
GO:0010506 regulation of autophagy
GO:0014706 striated muscle tissue development
GO:0016236 macroautophagy
GO:0016241 regulation of macroautophagy
GO:0031667 response to nutrient levels
GO:0031668 cellular response to extracellular stimulus
GO:0031669 cellular response to nutrient levels
GO:0031929 TOR signaling
GO:0032006 regulation of TOR signaling
GO:0032007 negative regulation of TOR signaling
GO:0034198 cellular response to amino acid starvation
GO:0035904 aorta development
GO:0035909 aorta morphogenesis
GO:0038202 TORC1 signaling
GO:0042594 response to starvation
GO:0044088 regulation of vacuole organization
GO:0048514 blood vessel morphogenesis
GO:0048738 cardiac muscle tissue development
GO:0048844 artery morphogenesis
GO:0060021 palate development
GO:0060537 muscle tissue development
GO:0060840 artery development
GO:0071496 cellular response to external stimulus
GO:1902115 regulation of organelle assembly
GO:1902532 negative regulation of intracellular signal transduction
GO:1905037 autophagosome organization
GO:2000785 regulation of autophagosome assembly
Molecular Function GO:0005096 GTPase activator activity
GO:0008047 enzyme activator activity
GO:0030695 GTPase regulator activity
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component GO:0035859 Seh1-associated complex
GO:1990130 Iml1 complex
> KEGG and Reactome Pathway
 
KEGG hsa04150 mTOR signaling pathway
Reactome -
Summary
SymbolNPRL3
NameNPR3-like, GATOR1 complex subunit
Aliases CGTHBA; RMD11; MARE; HS-40; conserved gene telomeric to alpha globin cluster; C16orf35; chromosome 16 open r ......
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NPRL3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNPRL3
NameNPR3-like, GATOR1 complex subunit
Aliases CGTHBA; RMD11; MARE; HS-40; conserved gene telomeric to alpha globin cluster; C16orf35; chromosome 16 open r ......
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NPRL3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.68; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolNPRL3
NameNPR3-like, GATOR1 complex subunit
Aliases CGTHBA; RMD11; MARE; HS-40; conserved gene telomeric to alpha globin cluster; C16orf35; chromosome 16 open r ......
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NPRL3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2460.389
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.060.974
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3850.769
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1140.731
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0380.985
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.310.909
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0720.814
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1050.934
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0830.955
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1830.903
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2040.925
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0570.322
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NPRL3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNPRL3
NameNPR3-like, GATOR1 complex subunit
Aliases CGTHBA; RMD11; MARE; HS-40; conserved gene telomeric to alpha globin cluster; C16orf35; chromosome 16 open r ......
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NPRL3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNPRL3
NameNPR3-like, GATOR1 complex subunit
Aliases CGTHBA; RMD11; MARE; HS-40; conserved gene telomeric to alpha globin cluster; C16orf35; chromosome 16 open r ......
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NPRL3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NPRL3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNPRL3
NameNPR3-like, GATOR1 complex subunit
Aliases CGTHBA; RMD11; MARE; HS-40; conserved gene telomeric to alpha globin cluster; C16orf35; chromosome 16 open r ......
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NPRL3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNPRL3
NameNPR3-like, GATOR1 complex subunit
Aliases CGTHBA; RMD11; MARE; HS-40; conserved gene telomeric to alpha globin cluster; C16orf35; chromosome 16 open r ......
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NPRL3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNPRL3
NameNPR3-like, GATOR1 complex subunit
Aliases CGTHBA; RMD11; MARE; HS-40; conserved gene telomeric to alpha globin cluster; C16orf35; chromosome 16 open r ......
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NPRL3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNPRL3
NameNPR3-like, GATOR1 complex subunit
Aliases CGTHBA; RMD11; MARE; HS-40; conserved gene telomeric to alpha globin cluster; C16orf35; chromosome 16 open r ......
Chromosomal Location16p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NPRL3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.